Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Odonate Inc | 49.9M | -1,254.8x | --- |
Lexaria Bioscience Corp | 37.7M | -4.8x | --- |
Cellectar Biosciences Inc | 64.1M | -0.9x | --- |
Akari Therapeutics PLC | 30.7M | -0.4x | --- |
KALA BIO Inc | 30.2M | -0.5x | --- |
PolyPid Ltd | 23.3M | -0.5x | --- |
Odonate, Inc., formerly Odonate Therapeutics, Inc., is a pharmaceutical company. The Company is focused on the development of tesetaxel, an investigational, orally administered chemotherapy agent that belongs to a class of drugs known as taxanes, which are used in the treatment of cancer. The Company is no longer in development of tesetax.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $49.9M |
---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 2.9K |
Odonate Inc does not pay a dividend. | |
Beta | 0.09 |
EPS | $-13.59 |
Book Value | $17.65 |
P/E Ratio | -1,254.8x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.